OverviewSuggest Edit

Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome. The Company is also developing Korlym in different combinations to treat patients with triple-negative breast cancer and metastatic castration-resistant prostate cancer. In addition, it develops product candidates for the treatment of Cushing's syndrome and solid-tumor cancers.

TypePublic
Founded1998
HQMenlo Park, CA, US
Websitecorcept.com
Employee Ratings3.1
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)206(+25%)
Job Openings14
Revenue (FY, 2020)$353.9 M(+16%)
Share Price (Dec 2021)$19.8(+2%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Corcept Therapeutics

James N. Wilson

James N. Wilson

Chairman of the Board
Hazel Hunt

Hazel Hunt

Chief Scientific Officer
Joseph K. Belanoff

Joseph K. Belanoff

Chief Executive Officer, President and Director
Amy Flood

Amy Flood

Chief Human Resources, Communications Officer
Atabak Mokari

Atabak Mokari

Chief Financial Officer
William Guyer

William Guyer

Chief Development Officer
Show more

Corcept Therapeutics Office Locations

Corcept Therapeutics has an office in Menlo Park
Menlo Park, CA, US (HQ)
149 Commonwealth Dr
Show all (1)

Corcept Therapeutics Financials and Metrics

Corcept Therapeutics Revenue

Corcept Therapeutics's revenue was reported to be $353.87 m in FY, 2020
USD

Revenue (Q1, 2021)

79.4m

Gross profit (Q1, 2021)

78.2m

Gross profit margin (Q1, 2021), %

98.4%

Net income (Q1, 2021)

23.5m

EBIT (Q1, 2021)

19.6m

Market capitalization (31-Dec-2021)

2.2b

Closing stock price (31-Dec-2021)

19.8

Cash (31-Mar-2021)

52.4m

EV

2.2b
Corcept Therapeutics's current market capitalization is $2.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.3m10.4m26.6m50.3m81.3m159.2m251.2m306.5m353.9m

Revenue growth, %

156%89%62%

Cost of goods sold

91.0k143.0k882.0k1.4m2.1m3.6m5.2m5.5m5.6m

Gross profit

3.2m10.2m25.7m48.9m79.3m155.6m246.0m301.0m348.3m
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Corcept Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Corcept Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Corcept Therapeutics Online and Social Media Presence

Embed Graph

Corcept Therapeutics Company Culture

  • Overall Culture

    F

    35/100

  • CEO Rating

    F

    53/100

  • Compensation

    C

    70/100

Learn more on Comparably

Corcept Therapeutics News and Updates

Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer

MENLO PARK, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, tod…

Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer

MENLO PARK, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, tod…

CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Inc. on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of Corcept stockholders. Our investigation con…

Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares

MENLO PARK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, tod…

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, toda…

Corcept Therapeutics (CORT) Alert: Shareholder Class Action In Part Survives Motion to Dismiss; Should Management be Held Accountable for Investors' Losses? Contact Johnson Fistel

SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Corcept Therapeutics, Inc. (NASDAQ: CORT) against certain of its officers and directors. Specifically, a class-action lawsuit pending in the Northern District of California issued an ord…
Show more

Corcept Therapeutics Blogs

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update Content Import Wed, 11/03/2021 - 16:11 Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update November 3, 2021 at 4:05 PM EDT Thi…

William Guyer to Join Corcept as Chief Development Officer

William Guyer to Join Corcept as Chief Development Officer ronfrancis.gon… Thu, 08/12/2021 - 17:00 William Guyer to Join Corcept as Chief Development Officer August 12, 2021 at 5:00 PM EDT This release is a backfill from a News Wire General …

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update Content Import Thu, 07/29/2021 - 16:09 Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update July 29, 2021 at 4:05 PM EDT This…

Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif. , July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021 . The company will also host a conference call that day at 5:00 p.m.

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results

In a 178-patient, controlled, Phase 2 trial, women with platinum-resistant ovarian cancer who received relacorilant plus nab-paclitaxel experienced improved progression free survival (PFS) compared to women who received nab-paclitaxel alone, with comparable safety and tolerability; planning

Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication

MENLO PARK, Calif. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today
Show more

Corcept Therapeutics Frequently Asked Questions

  • When was Corcept Therapeutics founded?

    Corcept Therapeutics was founded in 1998.

  • Who are Corcept Therapeutics key executives?

    Corcept Therapeutics's key executives are James N. Wilson, Hazel Hunt and Joseph K. Belanoff.

  • How many employees does Corcept Therapeutics have?

    Corcept Therapeutics has 206 employees.

  • What is Corcept Therapeutics revenue?

    Latest Corcept Therapeutics annual revenue is $353.9 m.

  • What is Corcept Therapeutics revenue per employee?

    Latest Corcept Therapeutics revenue per employee is $1.7 m.

  • Who are Corcept Therapeutics competitors?

    Competitors of Corcept Therapeutics include Baylor Scott & White Research Institute, Telix Pharmaceuticals and Plus Therapeutics.

  • Where is Corcept Therapeutics headquarters?

    Corcept Therapeutics headquarters is located at 149 Commonwealth Dr, Menlo Park.

  • Where are Corcept Therapeutics offices?

    Corcept Therapeutics has an office in Menlo Park.

  • How many offices does Corcept Therapeutics have?

    Corcept Therapeutics has 1 office.